Sentences with phrase «pharmacokinetic properties of»
The pharmacokinetic properties of vitamins D2 and D3 differ, with more consistent and higher serum concentrations of 25 (OH) D after vitamin D3 supplementation.
https://www.westonaprice.org/
Southern Research has been awarded a new, five - year Indefinite - Delivery Indefinite - Quantity (IDIQ) contract from the National Cancer Institute to investigate the pharmacokinetic properties of antitumor and other therapeutic agents of interest -LSB-...]
We then explored pharmacokinetic properties of RIPK2 inhibitor 1 in the sera of mice.
The physicochemical and mouse pharmacokinetic properties of BAZ2 - ICR were assessed.
The pharmacokinetic properties of J147 after a single dose of 20 mg / kg in mice show brain levels of about 600 nM at 2 h, over 10-fold above its EC50 in some cell culture neuroprotection assays [7], with a brain to blood ratio of approximately 0.5.
Not exact matches
«Perhaps giving a person the right dose, at just the right time, of a drug with just the right pharmacokinetic properties so its effect will wear off at the right time would work a lot better than bombarding the brain with benzodiazepines, such as Valium, that knock out the entire brain.»
The prototype of such bis - macrocycles, plerixafor, was used in a recent study as a starting point for structural modification, in order to identify compounds endowed with a similar antiviral activity and improved pharmacokinetic properties [94].
Replacement of the side chain with an isopropyl group led to the most potent compound 88, showing an IC50 of 2 nM for antiviral activity and suitable pharmacokinetic properties.
In general, genetic polymorphisms result in alterations of pharmacokinetic and / or pharmacodynamics properties which are then reflected in therapy outcomes that range from potentially life - threatening adverse effects to inadequate therapeutic response.
These compounds; CHDI - 00390576 and CHDI - 00484077, differ as to the warhead used to engage the Zn2 + ion in the catalytic site of Class IIa HDACs (hydroxamate versus trifluoromethyloxadiazole), their ability to disrupt HDAC4: HDAC3 associations, their pharmacokinetic (PK) and pharmacodynamic (PD) properties and their selectivity over Class I / IIb HDACs.
They provide researchers with access to additional skills, medicinal chemistry, pharmacokinetics, and evaluations of drug - like properties, which helps them determine whether their discoveries could lead to viable drugs to treat diseases.